Avicanna IncOTCQX International:AVCNFView on Canadian Exchange
- LAST PRICE0.2806
- TODAY'S CHANGE (%)-0.0200 (-6.6534%)
- Bid / Lots0.2533/ 100
- Ask / Lots0.2646/ 40
- Open / Previous Close0.2825 / 0.3006
- Day Range
- 52 Week Range
- Volume6,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AVCNF |
|---|---|---|
| 10:06 ET | 1000 | 0.2806 |
Apr 18, 2024
Avicanna Announces Closing of Non-brokered Private Placement, from 5:00PM ET on Thursday Apr 18, 2024 by Dow Jones
5:00PM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 10, 2024
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study, from 8:37AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:37AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
*DJ Avicanna 2023 Rev $16.8M >AVCN.T, from 7:32AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:32AM ET on Tuesday Apr 02, 2024 by Dow JonesAvicanna Reports Full Year 2023 Audited Financial Results, from 7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 27, 2024
Avicanna Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation, from 8:02AM ET on Wednesday Mar 27, 2024 by Dow Jones
8:02AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Avicanna Inc | 35.2M | 0.0x | --- |
Company Information
Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patients’ needs and enhances the patient's journey.
Contact Information
- Headquarters
- 480 UNIVERSITY AVENUE, SUITE 1502TORONTO, ON, Canada M5G 1V2
- Phone
- 647-243-5283
- Fax
- 647-243-5283
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.2M |
|---|---|
Revenue (TTM) | $16.8M |
Shares Outstanding | 92.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.51 |
EPS | $-0.10 |
Book Value | $0.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -49.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
